M&T Bank Corp Increases Stock Position in Certara, Inc. (NASDAQ:CERT)

M&T Bank Corp increased its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 41.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 163,933 shares of the company’s stock after purchasing an additional 48,381 shares during the period. M&T Bank Corp owned 0.10% of Certara worth $1,746,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its position in shares of Certara by 8.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 757,392 shares of the company’s stock valued at $8,066,000 after buying an additional 57,817 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Certara during the fourth quarter worth $148,000. Bank of New York Mellon Corp grew its holdings in shares of Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock valued at $21,248,000 after buying an additional 1,253,385 shares during the last quarter. Private Advisor Group LLC acquired a new position in shares of Certara in the 4th quarter valued at $251,000. Finally, Venturi Wealth Management LLC increased its holdings in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CERT has been the subject of a number of research reports. William Blair reaffirmed a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target on the stock. Stephens restated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Finally, Barclays increased their target price on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Certara presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Price Performance

CERT stock opened at $11.73 on Monday. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market capitalization of $1.89 billion, a PE ratio of -58.65, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The business has a 50 day simple moving average of $12.56 and a 200-day simple moving average of $11.61.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.